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Abstract	1	
Background	&	Aims	2	
Bioelectrical	impedance	vector	analysis	(BIVA)	is	a	non-invasive	method	of	measuring	3	
human	body	composition	.	This	offers	the	potential	to	evaluate	nutritional	and	hydration	4	
states	in	cancer.	Analysis	of	BIVA	data	using	z-score	(the	number	of	standard	deviations	5	
away	from	the	mean	value	of	the	reference	group)	has	the	potential	to	facilitate	6	
comparisons	between	different	cancer	types.	7	
The	aim	of	this	study	was	to	use	the	BIVA	Reactance	(R)	/	Reactance	(Xc)	z-score	method	to	8	
evaluate	body	composition	differences	in	cancer,	using	data	from	previously	published	BIVA	9	
studies.	10	
Methods	11	
Previous	studies	using	BIVA	in	cancer	were	identified	from	the	literature.	Bioimpedance	12	
measures	were	analysed	using	the	BIVA	RXc	z-score	graph.	The	mean	vector	impedance	13	
measures	from	the	studied	populations	were	transformed	into	standard	deviates	(with	14	
respect	to	the	mean	and	standard	deviation	of	the	reference	populations).	Body	15	
composition	was	classified	according	to	vector	placement	(i.e.	normal	athletic,	cachectic,	16	
oedematous	and	dehydrated).	17	
Results	18	
Seven	male	and	three	cancer	female	populations	were	evaluated.	Body	composition	was	19	
classified	as	normal	for	the	majority	(n=5),	followed	by	cachexia	(n=4)	and	athletic	(n=1)	20	
respectively.		Variation	in	body	composition	for	the	studied	populations	appeared	to	be	21	
related	to	factors,	such	as	gender,	disease	type	and	severity.		22	
		 3	
Conclusions	23	
The	BIVA	RXc	z-score	method	has	potential	to	evaluate	body	composition	differences	24	
between	cancer	groups.	This	method	can	study	body	composition,	according	to	cancer	type,	25	
stage,	gender	and	ethnicity.	Limitations	of	the	method	relate	to	issues	appropriate	26	
reference	populations	and	variability	between	bioimpedance	analysers.	Better	body	27	
composition	assessment	has	the	potential	to	personalise	therapeutic,	nutrition	and	28	
hydration	management.	Further	work	is	essential	to	facilitate	in-depth	evaluation	in	these	29	
areas,	in	order	to	achieve	meaningful	use	of	the	BIVA	method	in	clinical	practice.				30	
Key	words	31	
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Introduction	34	
People	with	advanced	cancer	commonly	experience	body	composition	changes	(i.e.	fat,	35	
bone,	water	and	muscle).	[1-4].	Evidence	demonstrates	that	cancer	patients	with	reduced	36	
physical	function	report	poorer	quality-of-life[5]	and	shorter	life	expectancy	compared	to	37	
other	patients.[6]Bioelectrical	impedance	analysis	(BIA)	is	a	non-invasive	method	of	38	
measuring	human	body	composition	(i.e.	analysis	of	fat,	bone,	water	and	muscle).[7]	BIA,	39	
delivers	a	low	frequency	electrical	current	and	works	on	the	principle	that	fluid	and	cellular	40	
structures	will	provide	different	levels	of	resistance	to	an	electrical	current	as	it	passes	41	
through	a	living	system.[7]	BIA	provides	the	following	measurements:	Resistance	(R	-	Ohms),	42	
assessing	cellular	hydration;	Reactance	(Xc	-	Ohms),	assessing	tissue	integrity	and	Phase	43	
Angle	(PA	-	degrees),	representing	the	arc-tangent	between	R	and	Xc	(PA	is	a	useful	44	
indicator	of	health	and	prognosis.[7]).	BIA	technology	has	been	used	to	evaluate	hydration	45	
and	nutrition	in	several	populations.[7,	8]		46	
Bioelectrical	impedance	vector	analysis	(BIVA)	to	assess	body	47	
composition	in	advanced	illness	48	
Statistical	vector	analysis	of	BIA	data	enables	further	analysis	of	human	body	composition	to	49	
be	conducted.[9]	Bioelectrical	impedance	vector	analysis	(BIVA)	uses	graphical	vectors	to	50	
analyse	BIA	data.[8]	Using	this	method,	impedance	(Z)	is	plotted	as	a	vector	from	its	51	
components	R	(X	axis)	and	Xc	(Y	axis),	after	being	standardized	by	height	(H).	The	RXc	graph	52	
represents	the	sex	and	race-specific	tolerance	intervals	of	a	comparative	reference	53	
population.	Tolerance	ellipses	are	plotted	on	the	RXc	graph	to	represent	the	50%,	75%	and	54	
95%	centiles	(i.e.	confidence	intervals)	for	the	population.	(Figure	1	-	The	RXc	graph	with	55	
		 5	
95%,	75%	and	50%	tolerance	ellipses.	Reproduced	and	modified	with	permission).[10]	The	56	
advantage	of	this	method	is	that	it	allows	information	to	be	obtained	simultaneously	about	57	
changes	in	tissue	hydration	or	soft-tissue	mass,	independent	of	regression	equations,	or	58	
body	weight.	Therefore,	BIVA	can	be	interpreted	accurately	even	if	patients	are	at	extremes	59	
of	weight	or	volume	distribution.	BIVA	has	been	used	to	study	hydration	status	in	a	variety	60	
of	different	diseases[11-19]	and	to	undertake	general	body	composition	assessments	in	lung	61	
cancer[18,	20]	and	cancers	of	the	head	and	neck.[21]	Our	previous	research	used	the	BIVA	62	
method	to	examine	associations	between	hydration	status,	symptoms	and	survival	in	63	
advanced	cancer	patients.[22]		64	
BIVA	RXc	z-score	analysis	facilitates	comparisons	between	65	
populations	66	
Statistical	conversion	of	BIVA	measurements	to	z-scores	enables	researchers	to	compare	67	
body	composition	of	different	study	populations.[23]	Piccoli	et	al[23]	used	this	method	to	68	
compare	BIVA	data	for	a	variety	of	disease	groups.	To	date,	no	studies	have	used	the	BIVA	69	
RXc	z-score	method	to	synthesise	cancer	populations	evaluated	with	BIVA.	Consequently,	70	
there	is	potential	to	use	the	BIVA	Z	score	method	to	evaluate	body	composition	by	cancer	71	
type	and	severity.	Such	information	will	potentially	help	support	nutritional	assessment	and	72	
management	in	cancer.	73	
Aim	74	
To	determine	the	feasibility	of	the	using	the	BIVA	RXc	z-score	method	to	compare	body	75	
composition	in	cancer	populations	using	published	bioimpedance	data.	76	
	77	
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Materials	and	Methods	78	
A	systematic	review	reporting	BIVA	in	advanced	cancer	(published	by	Nwosu	et	al	2013[8])	79	
was	used	to	identify	previous	studies	using	BIVA	to	evaluate	body	composition	in	advanced	80	
cancer.	Further,	an	electronic	search	of	the	literature	using	MEDLINE,	EMBASE	and	Pubmed	81	
(combining	keywords	of	“bioelectrical	impedance	vector	analysis"	and	“Neoplasms[MesH]”,	82	
limited	to	English	language	and	humans)	was	conducted	to	identify	relevant	studies.		83	
Inclusion	criteria	for	studies	84	
Articles	were	eligible	for	review	provided	that	they	involved	the	use	of	BIA	in	adult	humans	85	
with	cancer.	The	following	data	was	required	for	the	z-score	analysis:	(i)	R/H	(Ohm/m)	and	86	
Xc/H	(Ohm/m)	mean	for	the	studied	population,	(ii)	studied	population	size,	(iii)	sex-specific	87	
bioimpedance	data	and	(iv)	details	of	the	reference	population	used	for	the	analysis.	88	
Minimum	standards	for	the	reference	population	were	as	follows:	the	total	sample	size	89	
n≥100,	the	R/H	(Ohm/m)	mean,	R/H	(Ohm/m)	standard	deviation	(SD),	Xc/H	(Ohm/m)	mean	90	
and	Xc/H	(Ohm/m)	SD.	The	Picolli	1995	reference	population	(Caucasian	Europeans,	males	91	
(n=354)	and	females	(n=372)	aged	18	-	85	years,	body	mass	index	(BMI)	16	-31	kg/m2,	Italy,	92	
analyser	=	Akern-RJL	systems	[24])	was	used	for	studies	which	did	not	meet	the	minimum	93	
reference	standard.	We	selected	the	Piccoli	data	as	it	was	the	most	commonly	selected	94	
reference	population	for	studies	evaluating	the	BIVA	method.		95	
Exclusion	criteria	for	studies	96	
The	following	articles	were	excluded:	Non	English	studies;	those	reporting	paediatric	97	
populations;	absent	data	to	facilitate	the	BIVA	Z	score	analysis	(see	inclusion	criteria).	98	
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	99	
BIVA	software	and	z-score	analysis	100	
BIVA	was	conducted	using	software	developed	by	Professor	Antonio	Piccoli,	University	of	101	
Padova.[25]		The	mean	vector	impedance	measures	for	study	populations	were	transformed	102	
into	standard	deviates	with	respect	to	the	mean	and	standard	deviation	and	compared	103	
against	their	reference	population.[24]	The	z-score	is	the	number	of	standard	deviations	104	
away	from	the	mean	value	of	the	reference	group.[26]	Z-scores	can	provide	information	105	
about	an	individual	measured	score,	relative	to	others	in	the	distribution.[27]	106	
Transformation	of	the	BIVA	measurements	to	z-scores	facilitates	comparison	between	107	
different	conditions	and	diseases	(Figure	2).	Using	the	RXc	z-score	graph,	individuals	within	108	
the	50%	tolerance	ellipse	are	considered	to	have	normal	body	composition,	whereas	those	109	
in	the	75%	and	95%	tolerance	ellipses	are	abnormal.[25]		110	
Vectors	were	plotted	on	the	RXc	z-score	graph	to	facilitate	data	comparison.	Vectors	plotted	111	
within	the	50%	tolerance	ellipse	were	considered	normal.	Based	on	data	from	the	Piccoli	112	
study,[23]	the	BIVA	RXc	z-score	graph	was	divided	into	four	quadrants	to	classify	body	113	
composition	of	populations	within	the	75%	and	95%	(i.e.	abnormal)	tolerance	ellipses.	These	114	
quadrants	were	(i)	Athletic	(high	cell	mass),	top	left,	(ii)	Cachexia	(low	cell	mass),	bottom	115	
right;	(iii)	Oedema,	bottom	left	and	(iv)	Dehydrated,	top	right	(Figure	2).	Body	composition	116	
was	determined	according	to	the	plotted	vector	position.	Further	details	on	the	equations	117	
used	to	calculate	the	RXc	Z	score	graph	analysis	are	available	in	the	appendix.	118	
Ethical	Statement	119	
This	study	was	a	secondary	analysis	of	previously	published	research.	Therefore,	ethical	120	
approval	was	not	required.	121	
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Results	122	
The	literature	search	returned	15	full	text	articles	using	BIVA	in	people	with	cancer	(Figure	123	
3).	Two	of	these	articles	were	rejected	as	they	are	not	specific	to	patients	with	advanced	124	
cancer.	Two	studies	(Lundberg	et	al[28]	and	Gnagnarella	et	al[29])	were	excluded	as	125	
insufficient	data	was	available	to	enable	the	RXc	z-score	analysis	to	be	conducted.	Of	the	126	
remaining	eleven	studies,	some	presented	the	same	BIVA	data.	These	included	two	different	127	
studies,	which	both	reported	data	for	the	same	breast	cancer	sample.[30,	31]	Similarly,	two	128	
studies	reported	data	for	the	same	head	and	neck	cancer	sample.[21,	32]	We	grouped	the	129	
relevant	studies	together	to	avoid	confusion.	Consequently,	nine	of	the	eleven	eligible	130	
studies	were	included.	These	nine	studies	provided	data	for	seven	male	and	three	female	131	
populations	(Table	1).	The	studies	described	different	cancer	types	and	stages,	which	132	
included	advanced	cancer	of	different	origin;[22]	lung	cancer	(including	a	sample	of	patients	133	
in	remission),[18,	20]	breast	cancer,[30]	head	and	neck	cancer[21,	33]	and	gynaecological	134	
cancer.[34]	Details	of	patient	demographics,	type	of	analyser	and	BIVA	z-score	analysis	are	135	
presented	in	Table	1.	136	
BIVA	RXc	z-score	analysis	137	
The	reference	population	of	Piccoli	et	al[24]	was	used	as	the	chosen	reference	population	138	
for	the	authors	of	the	Cardoso[34]	and	Nwosu	studies.	However,	the	seven	populations	139	
described	by	Toso	et	al[18,	20]	and	Malecka-Massalska[21,	31,	35]	[30,	32]	used	control	140	
groups	with	sample	sizes	of	n<100	as	a	reference.	We	used	the	Piccoli	data[24]	as	a	141	
reference	population	for	these	studies.	Consequently,	the	Piccoli	reference	population	was	142	
used	as	the	reference	for	all	studies	in	this	paper.	143	
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The	z-score	analysis	is	presented	in	Figure	4	and	Table	2	(supplementary	file).	Five	144	
populations	were	normal	(50%	tolerance	ellipse).	These	were	the	male	and	female	cohorts	145	
with	various	cancers	(Nwosu	et	al	2016[22]),	males	with	lung	cancer	in	remission(Toso	el	al	146	
2003[18]),	males	patients	with	stage	III	lung	cancer	(Toso	el	al	2000	[20])	and	females	with	147	
gynaecological	cancer	(Cardoso	et	al	2017[34]).		Comparatively	greater	cell	mass	was	noted	148	
in	females	with	the	newly	diagnosed	breast	cancer[30]	(the	vector	was	superior	to	the	95%	149	
tolerance	ellipse	of	the	athletic	quadrant)	had.	Four	groups	were	cachectic	(vectors	within	150	
the	75%	and	95%	tolerance	ellipse).	This	included	males	with	stage	IV	lung	cancer		(Toso	et	151	
al	2000[20]	-	75%	tolerance	ellipse),	males	with	local	and	disseminated	lung	cancer(Toso	et	152	
al	2003[18]	-	75%	tolerance	ellipse),	and	two	populations	of	males	with	head	and	neck	153	
cancer	(Malecka-Massalska	et	al	2013[33]–	75%	tolerance	ellipse,	and	Malecka-Massalska	et	154	
al	2012,	2014[21,	32]	-	95%	tolerance	ellipse).	.	155	
Discussion	156	
Main	findings	157	
Seven	male	and	three	cancer	female	populations	were	evaluated.	Body	composition	was	158	
classified	as	normal	for	the	majority	(n=5),	followed	by	cachexia	(n=4)	and	athletic	(n=1)	159	
respectively.		Variation	in	body	composition	for	the	studied	populations	appeared	to	be	160	
related	to	factors,	such	as	gender,	disease	type	and	severity.		161	
Strengths	and	uniqueness	of	this	study	162	
This	is	first	study	to	use	the	BIVA	z-score	method	to	compare	body	composition	in	cancer	163	
populations,	using	data	from	previously	published	bioimpedance	data.	BIVA	offers	164	
advantages	over	traditional	methods	of	body	composition	assessment,	due	to	its	non-165	
invasive	nature	and	simplicity.	BIVA	has	methodological	advantage	over	traditional	BIA	166	
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calculations	due	to	its	independence	of	regression	equations	(which	lack	accuracy	in	167	
cancer[7]).	Furthermore,	BIVA	can	facilitate	longitudinal	assessments	to	evaluate	body	168	
compositionchanges	over	time.	These	properties	are	useful	to	evaluate	nutrition	and	169	
hydration	in	people	affected	by	cancer,	who	are	unable	to	tolerate	more	invasive	methods	170	
of	assessment.	This	research	demonstrates	the	potential	to	use	published	BIVA	data	for	171	
larger	analysis.		172	
Comparison	with	previous	work	173	
The	only	previous	study	to	use	BIVA	RXc	z-scores	in	cancer	was	the	Piccoli	et	al	2002.[23]	174	
Piccoli	plotted	data	from	the	vector	point	for	males	with	stage	IV	lung	cancer	(Toso	et	al	175	
2000[20])	within	the	cachexia	quadrant	(75%	tolerance	ellipse).	Our	data	builds	on	Piccoli’s	176	
study	and	describes	how,	in	addition	to	Toso’s	stage	IV	lung	cancer	data,	three	other	177	
populations	were	also	classified	as	cachectic.	This	included	a	lung	cancer	sample	with	local	178	
and	disseminated	disease,[18]	and	two	head	and	neck	cancer	cohorts[21,	32,	33]).	The	179	
vectors	for	the	advanced	cancer	population	described	by	Nwosu	et	al[22]	(although	plotted	180	
within	the	normal	50%	ellipse)	were	in	a	similar	position	to	the	lung	cancer	studies	by	Toso	181	
et	al,	[18,	20].	This	suggests	similarity	between	these	groups	(i.e.	low	muscle	mass,	with	risk	182	
of	cachexia),	even	though	body	composition	was	classified	as	normal.	Therefore,	183	
interpretation	of	BIVA	Rxc	z-score	data	requires	consideration	of	clinical	factors	in	addition	184	
to	BIVA.	185	
	Previous	work	illustrates	how	patients	with	cancer	are	prone	to	develop	cachexia	as	their	186	
condition	progresses.[1,	36]	However,	data	about	the	stage	of	cancer	was	only	available	for	187	
two	populations.	It	is	possible	that	stratification	of	data	by	cancer	stage	may	have	188	
demonstrated	that	individuals	with	more	severe	cancer	were	more	likely	to	be	cachexic.	189	
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Furthermore,	assessments	at	different	points	in	the	disease	trajectory	may	demonstrate	190	
changing	body	composition	over	time.	191	
Our	data	demonstrates	that	body	composition	appeared	to	be	related	to	cancer	type,	192	
disease	severity	and	gender.[37]	For	example,	females	with	breast[30]	and	gynaecological	193	
cancers[34]	had	increased	cell	mass	compared	to	other	populations	(demonstrated	by	more	194	
superior	vector	placement).	Two	factors	may	explain	this	difference.	Firstly,	individuals	with	195	
breast	and	gynaecological	cancer	were	comparatively	younger	than	other	groups	(the	mean	196	
age	for	the	breast	and	gynaecological	cancer	groups	were	53	and	60	years	respectively,	197	
whereas	most	other	populations	were	aged	>60	years).	Secondly,	these	patients	were	198	
recruited	at	diagnosis,	whereas	participants	in	other	studies	were	recruited	later	in	their	199	
illness.		200	
Limitations	201	
A	limitation	of	this	study	is	that	nutritional	screening	tools	were	not	used	in	all	studies,	202	
which	makes	nutritional	based	comparisons	difficult.	The	Subjective	Global	Assessment	203	
(SGA	-	a	simple	bedside	method	of	assessing	the	risk	of	malnutrition	[38])	was	used	in	the	204	
majority	studies.	Only	one	study	(Cardoso	et	al[34])	reported	body	mass	index	(BMI)	data	205	
according	to	the	requirements	of	the	European	Society	for	Clinical	Nutrition	and	206	
Metabolism	(ESPEN)	malnutrition	criteria.[39]	Therefore,	our	ability	to	evaluate	how	BIVA	207	
RXc	z-scores	relates	to	nutritional	states	is	limited.	208	
A	small	number	of	studies	were	evaluated	in	this	analysis	and	the	majority	of	participants	209	
included	in	the	studies	were	from	white,	European	or	North	American	populations,	which	210	
limits	our	ability	to	extrapolate	the	findings.	The	under-representation	of	non-white	groups	211	
in	these	studies	may	be	due	to	various	factors,	such	as	language	and	cultural	barriers.[40]	212	
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Further,	as	this	analysis	only	included	English	language	studies,	it	is	possible	that	studies	213	
using	BIVA	in	different	cultural	contexts	were	excluded.		214	
The	lack	of	BIVA	research	in	females	limits	the	ability	to	extrapolate	results	to	women.	215	
Females	differ	physiologically	to	males	(generally	more	body	fat,	less	body	water,	shorter	216	
height	and	reduced	muscle	mass	compared	to	men[41,	42]).	Of	the	three	studies	including	217	
women,	two	studied	female	specific	cancers	(breast[30,	31],	cervical[34])	and	one	studied	218	
with	a	mix	of	cancer	types.[22]	Therefore,	no	studies	in	the	literature	provide	meaningful	219	
female-specific	BIVA	data	for	any	cancers,	other	than	those	affecting	the	breast	and	cervix.		220	
Our	findings	are	limited	by	a	lack	of	information	about	the	reasons	why	reference	221	
populations	were	chosen			Reference	populations	may	not	be	representative	of	the	studied	222	
population.	This	is	problematic	with	the	Cardoso	et	al[34]	study,	which	used	an	223	
inappropriate	reference	population	(European	white	adults)	for	their	analysis	of	a	Brazilian	224	
Pardo	(mixed	race)	sample.[34]	It	is	likely	this	population	was	chosen	due	to	the	lack	of	225	
other	suitable	reference	populations.	Furthermore,	seven	populations	used	small	control	226	
groups	(n<100)	as	their	reference,	which	are	inappropriate	due	to	their	small	size.	Although	227	
we	used	the	Piccoli	population	as	the	reference	for	these	studies,	other	reference	228	
population	may	have	been	more	appropriate.	This	demonstrates	the	challenges	of	using	the	229	
BIVA	Z	score	method	appropriately	when	there	is	variability	about	how	reference	230	
populations	are	selected.	231	
Different	bioimpedance	analysers	were	used	throughout	the	studies	included	in	this	232	
analyser.	This	may	result	in	slight	differences	in	reactance	and	resistance	values	which	may	233	
alter	the	BIVA	z-score	interpretation.	Finally,	an	inherent	limitation	of	the	BIVA	method	is	234	
that	it	is	a	qualitative	assessment	method	which	does	not	provide	absolute	values	of	body	235	
composition	metrics.[8]	Therefore,	the	method	is	unable	to	provide	quantitative	data	on	236	
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body	composition	variables	(e.g.	fat	free	mass,	and	fluid	volume).	This	is	why	stratification	237	
of	BIVA	data	according	to	clinical	variables	is	important	(e.g.	disease	stage,	type	and	238	
ethnicity),	in	order	to	determine	clinically	meaningful	outcomes.	239	
Implications	to	clinical	practice	and	policy	240	
This	analysis	supports	previous	data	that	describes	how	body	composition	in	cancer	is	241	
related	to	a	number	of	factors	(e.g.	stage,	type	of	disease).[36,	43,	44]	This	study	242	
demonstrates	the	potential	to	use	the	BIVA	RXc	z-score	method	to	undertake	comparative,	243	
multi-group,	body	composition	analysis,	which	could	be	useful	to	compare	differences	in	244	
cancer	according	to	disease	stage	and	type.	This	has	the	potential	to	personalise	245	
therapeutic,	nutrition	and	hydration	based	interventions	according	to	an	individual’s	246	
physiology.	Although	the	BIVA	RXc	z-score	method	has	potential	use	in	clinical	practice,	we	247	
are	unable	to	recommend	its	routine	use	in	clinical	practice	(in	cancer),	due	to	the	limited	248	
number	of	studies	using	the	method	and	a	lack	of	data	to	inform	clinical	interpretation.	249	
Future	research	possibilities		250	
Further	research	studies	using	bioimpendence	are	needed	to	evaluate	differences	in	cancer,	251	
according	to	disease	type,	stage,	ethnicity	and	gender.	In	order	to	improve	the	clinical	252	
usefulness	of	BIVA,	future	bioimpedance	studies	should	report	all	the	relevant	data	(and	253	
standard	deviations)	required	to	conduct	BIVA[45]	(i.e.	age	(years),	Height	(m),	BMI	(Height	254	
(H)2/m),	weight(kg),	R	(Ohm),	R/H	(	Ohm/m),	Xc	(Ohm),	Xc/H	(	Ohm/m),	PA		(degrees)).	255	
Researchers	should	justify	the	reasons	for	the	choice	of	reference	populations,	stating	why	256	
the	chosen	population	is	best	suited	for	their	analysis.	Inclusion	of	this	information	will	257	
enable	researchers	to	conduct	BIVA	analyses	without	needing	to	contact	investigators	for	258	
further	information.	Researchers	should	aim	to	develop	larger,	appropriately	powered,	259	
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reference	populations,	to	facilitate	stratification	(by	age,	gender,	ethnicity	and	other	clinical	260	
factors).	As	a	priority,	futures	studies	should	generate	data	for	non-white	and	female	261	
individuals.	262	
Conclusions	263	
The	BIVA	RXc	z-score	method	can	be	used	to	evaluate	body	composition	in	people	with	264	
cancer.	This	method	can	be	used	to	conduct	analysis	of	body	composition	according	to	265	
different	variables	such	as	cancer	type,	stage,	gender	and	ethnicity.	Improved	assessment	266	
will	lead	to	better	understanding	of	the	physiological	and	biological	processes	of	advanced	267	
cancer.	Consequently,	BIVA	may	help	healthcare	professionals	to	personalise	therapy	in	268	
patients	with	cancer	according	to	their	physiology.		269	
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Appendix	475	
Formulas	for	the	calculation	of	the	bio-impedance	confidence	and	476	
tolerance	ellipses		477	
The	following	section	has	been	adapted	(with	permission)	from	Piccoli	A	,	Pastori:	BIVA	478	
software.[25]	479	
Geometrical	parameters	for	drawing	the	RXc	Graph	and	the	RXc-480	
score	Graph	481	
Confidence	and	tolerance	intervals	can	be	calculated	for	the	bivariate	normal	482	
distribution.[46-50]	A	simple	linear	correlation	analysis	can	be	used	for	calculation	following	483	
appropriate	modification	of	the	equations.[9,	23]		484	
Given	n	pairs	of	observations	x	and	y,	with	standard	deviation	sx	and	sy,	and	correlation	485	
coefficient	r,	for	a	fixed	!	probability	level,	the	Snedecor's	Fα	value	is	taken	with	2	and	n-2	486	
degrees	of	freedom.	487	
RXc	Graph	488	
The	RXc	graph	semi-axes	(L1	and	L2)	and	the	slopes	(b1	and	b2	=	-1/b1),	of	the	axes	of	the	489	
100(1-α)%	confidence	and	tolerance	ellipses	(e.g.	α=	0.05,	0.25,	and	0.50	for	the	95th,	75th,	490	
and	50th	percentile,	respectively)	can	be	calculated	using	the	equations	2a	and	3a,	491	
respectively.	492	
RXc-score	graph	493	
The	parameters	of	tolerance	ellipses	of	bivariate	Z-scores	(RXc	Zscore	graph)	can	be	494	
calculated	accordingly,	using	equations	1b	and	2b.[23]	495	
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Equation	1	a		496	
"#, "% =497	
'. ) − 1 ,-. +	12. ± () − 1)(,-. + ,2.) 6 − 4	() − 1)6(1 − 86),-.	,2. 		498	
	499	
Equation	1	b	500	
9#, 9% = '.	 %	 : − # ± %	;	(: − #)	501	
	502	
Where	503	
K	=	F/n·(n-2)	for	confidence	ellipses	504	
K	=	F·(n+1)/n·(n-2)	for	tolerance	ellipses	505	
Equation	2	a	506	
<#, <% = <,−#< = (=>% − =?%)/%;=?=> ± # +	 (=>% − =?%)/%	;=?=>]%	507	
	508	
Equation	2b	509	
<#, <% = ±#	510	
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Figure	and	Table	Legends	511	
Table	1	Details	of	the	studies	included	in	the	BIVA	RXc	z-score	analysis		512	
Key	 Author	 Characteristics	 N	 Mean	
age	
(years)	
Gender	 BMI	
(kg/m2)	
Tolerance	 Body	
composition	
Analyser	
	 Nwosu	
2016[22]	
	
Mixed	cancer	
Males	(n=42)	mean	age	70.6	
(SD	11.0),	median	71.0)	BMI	
26.4	(SD	5.2)	predominantly	
Caucasian,	advanced	cancer	
with	different	disease	types.	
United	Kingdom.	
	
42	 70.60	 Male	 26.4	 50%	 Normal	 Analyzer	
The	EFG3	
ElectroFluidGraph	
Vector	Impedance	
Analyser	(Akern)	
p	 Nwosu	
2016[22]	
Mixed	cancer	
Female	(n=48)	mean	age	71.6	
(SD	13.3),	median	74,	BMI	24.1	
(4.7)	predominantly	Caucasian,	
with	different	disease	types.	
United	Kingdom.	
	
48	 76.10	 Female	 24.1	 50%	 Normal	 Analyzer	
The	EFG3	
ElectroFluidGraph	
Vector	Impedance	
Analyser	(Akern)	
¢	 Toso	
2000[20]		
lung	cancer	stage	IIIB	 33	 67.00	 Male	 25.0	 50%	 Normal	 Analyzer	
BIA-101,	RJL/Akern	
Systems,	Clinton	
Town-	ship,	MI,	USA	
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Males,	n=33.	Mean	age	67	(SD	
5.0),	BMI	25	(SD	5.5)	
Caucasian,	lung	cancer	stage	
IIIB.	Italy.	
	
	 Toso	
2000[20]		
lung	cancer	stage	IV	
Males,	n=30,	mean	age	64	(SD	
7.0),	BMI	25	(SD	3.1)	
Caucasian,	lung	cancer	stage	
IV,	Italy.		
	
30	 64.00	 Male	 25.0	 75%	 Cachexia	 Analyzer	
BIA-101,	RJL/Akern	
Systems,	Clinton	
Town-	ship,	MI,	USA	
△	 Malecka-
Massalska	
2012[30]	
2013[31]	
Breast	cancer	
Females,	n=34,	mean	age	
=53.88	(SD	10.84)	breast	
cancer	(n=34)	Poland.	
	
61	 53.88	 Female	 -	 95%	 Athletic	 Analyzer	
ImpediMed	
bioimpedance	analysis	
SFB7	BioImp	v1.55,	
Queensland,	Australia.	
£	 Malecka-
Massalska	
2012[21]	
2014	[32]	
Head	and	neck	cancer	
Males,	n=28,	mean	age	57.1	
(SD	7.3),	BMI	22.8	(5.0),	
Caucasian,	head	and	neck	
cancer.		
	
34	 57.10	 Male	 -	 95%	 Cachexia	 Analyzer	
ImpediMed	
bioimpedance	analysis	
SFB7	BioImp	v1.55,	
Queensland,	Australia.	
	 Toso	
2003[18]		
Lung	cancer	 56	 66.00	 Male	 25.0	 75%	 Cachexia	 Analyzer	
BIA-101,	RJL/Akern	
Systems,	Clinton	
Township,	MI,	USA	
		 25	
Males,	n=61,	mean	age	=66	
(SD	6),	BMI=	25	(SD	4),	
Caucasian,	lung	cancer,	locally	
advanced	and	disseminated.	
	
X	 Toso	
2003[18]	
Lung	cancer	in	remission	
Males,	n=31,	mean	age=	63	
(SD	10),	BMI=	25	(SD	4)	
Caucasian,	lung	cancer	in	
remission	(n=31)	
	
31	 63.00	 Male	 25.0	 50%	 Normal	 Analyzer	
BIA-101,	RJL/Akern	
Systems,	Clinton	
Township,	MI,	USA	
¸	 Melecka-
Massalska		
2013[33]	
Head	and	neck	cancer	
Males,	Caucasian	n=67,	mean	
age	=	56.8	(SD	7.9),	BMI	22.9	
(SD	4.4),	Caucasian,	head	and	
neck	cancer,	Poland.	
67	 67.00	 Male	 22.9	 75%	 Cachexia	 Analyzer	
ImpediMed	
bioimpedance	analysis	
SFB7	BioImp	v1.55,	
Queensland,	Australia.	
Ý	 Cardoso	
2017[34]	
Gynaecological	cancer	
Female,	n=208,	mean	age=	60	
(range	51-67),	BMI	=	
underweight	(12(6%),	normal	
52(25%),	overweight	55	(26%),	
obese	89	(43%).	White	
n=89(43%),	mixed	races	
92(42%),	Black	26(13%).	
Gynaecological	cancer.	Brazil	
	
208	 60.00	 Female	 -	 50%	 Normal	 BIA	450	Bioimpedance	
Analyzer,	
Biodynamics,	
Shoreline,	WA,	USA	
	513	
		 26	
RXc	z	score	data	analysed	with	BIVA	software	using	equations	included	in	the	appendix.	514	
	515	
Table	2:	Bioimpedance	Z	score	data	for	the	included	studies		516	
Study	details	 R/H	(Ohm/m)	
Xc/H	
(Ohm/m)	
Reference	population	data*	
Z(R)	
score	
Z(Xc)	
score	N	 R/H			
(Ohm/m)	
mean	
R/H			
(Ohm/m)	
SD	
Xc/H	
(Ohm/m)	
Mean	
Xc/H	
(Ohm/m)	
SD	
Males,	mixed	cancer	-	Nwosu	2016[22]	 306.6	 26.1	 354	 371.9	 43.2	 30.8	 7.2	 0.19	 -0.65	
Females,	mixed	cancer	-	Nwosu	2016[22]	 372.2	 29.1	 372	 298.6	 49.0	 34.4	 7.7	 0.01	 -0.69	
Males,	White,	Lung	cancer	stage	IIIB,	-	Toso	2000[20]	 302.0	 25.0	 354	 371.9	 43.2	 30.8	 7.2	 0.08	 -0.81	
Males,	White,	Lung	cancer	stage	IV,	-	Toso	2000[20]	 314.0	 24.0	 354	 371.9	 43.2	 30.8	 7.2	 0.36	 -0.94	
Females	with	breast	cancer	-	Malecka-Massalska	2012[30]	2013[31]	 377.54	 53.58	 372	 298.6	 49.0	 34.4	 7.7	 0.12	 2.49	
Males	with	head	and	neck	cancer-		Melecka-Massalska		2013[33]	 342.54	 27.62	 354	 371.9	 43.2	 30.8	 7.2	 1.02	 -0.44	
Males	with	lung	cancer	locally	advanced	and	disseminated	-	Toso	2003[18]	 317	 26.0	 354	 371.9	 43.2	 30.8	 7.2	 0.43	 -0.67	
Males	with	lung	cancer	in	remission	-	Toso	2003[18]	 287	 25.0	 354	 371.9	 43.2	 30.8	 7.2	 -0.27	 -0.81	
Males	with	head	and	neck	cancer	-	Melecka-Massalska		2013[33]	 327.01	 28.04	 354	 371.9	 43.2	 30.8	 7.2	 0.66	 -0.38	
Females	(mixed	race)	gynaecological	cancer	-	Cardoso	2017[34]	 349.8	 34.4	 372	 298.6	 49.0	 34.4	 7.7	 -0.45	 0.00	
*The	Piccoli	et	al	1995[24]	reference	population	data	was	used	for	all	studies	included	in	this	analysis.	BIVA	software	equations	are	included	in	517	
the	appendix.	518	
	519	
	 	520	
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Figure	1:	The	RXc	graph	with	95%,	75%	and	50%	tolerance	ellipses.	Reproduced	and	521	
modified	with	permission.[51]	522	
	523	
Figure	2:	The	BIVA	z-score	graph:	data	drawn	from	the	literature	and	plotted	on	the	RXc	z-524	
score	graph	after	transformation	of	the	impedance	measurements	from	several	disease	525	
groups	into	bivariate	z-scores	(with	respect	to	their	reference	population).	Modified	with	526	
permission.[23]	527	
Solid	and	open	circles	represent	male	and	female,	respectively.	A	forward	or	backward	528	
displacement	of	vectors	parallel	to	the	major	axis	of	ellipses	was	associated	with	529	
dehydration	or	fluid	overloading,	respectively,	reaching	extremes	out	of	the	poles.	Single	530	
score	vectors	are	from	athletes,[52]	obese	subjects	of	class	I	to	III[53]	or	patients	with	531	
chronic	renal	failure	in	conservative	treatment,	nephrotic	syndrome	(oedema),	lung	532	
cancer,[20]	acquired	immunodeficiency	syndrome	in	stages	WR	3	to	5	or	WR	6,[54]	and	533	
anorexia	nervosa.[55]	Repeated	score	vectors	are	from	climbers	before	and	after	high	534	
altitude	dehydration,[56]	Haemodialysis	patients,	either	lean[57]	or	obese,[53]	before	and	535	
after	fluid	removal	with	a	dialysis	session,	and	dehydrated	patients	with	cholera	before	and	536	
after	fluid	infusion.[12]	Vectors	above	or	below	the	major	axis	(meaning	upper	left	or	lower	537	
right	half	of	ellipses)	were	associated	with	more	or	less	cell	mass	in	soft	tissues,	respectively,	538	
with	extremes	along	the	minor	axis.	Abbreviations:	CRF	=	chronic	renal	failure;	HD=	539	
haemodialysis;	HDo=	obese	haemodialysis	patients;	HIV=	human	immunodeficiency	virus	540	
stages	1-6;	Ob/1-3=	obese	subjects	of	classes	I	to	III;	WR=	Walter	Reed	stages	1-6.		541	
Reproduced	with	permission.[23]	542	
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Figure	3:	Overall	selection	process	for	clinical	studies	included	in	the	BIVA	Z	score	analysis	543	
	544	
Figure	4:	RXc	z-score	graph	analysis	of	bioelectrical	impedance	vector	analysis	(BIVA)	data	545	
from	studies	of	patients	with	cancer.	546	
Data	drawn	from	the	literature	and	plotted	on	the	RXc-score	graph	after	transformation	of	547	
impedance	measurements	from	several	disease	groups	into	bivariate	Z	scores	(with	respect	548	
to	the	Piccoli	1995	reference	population[24]).	Further	details	of	the	equations	used	for	the	549	
analysis	are	available	in	the	appendix.550	
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